Monitoring rates of chlamydia re-testing within the English National Screening Programme, January 2013 to June 2017

Health Protection Report
Volume 12 Number 20
8 June 2018

Advanced Access report published 5 June 2018
Monitoring rates of chlamydia re-testing within the English National Screening Programme, January 2013 to June 2017

Key points

- Young adults who test positive for chlamydia are at high risk of repeat infection(s) [1-8].
- Since August 2013, the NCSP has recommended that young adults who test positive for chlamydia be routinely offered a re-test around three months after completing treatment.
- This analysis shows that, between January 2013 and June 2017, quarterly rates of re-testing 7-14 weeks after diagnosis peaked at 14.2% in October-December 2016 for non-specialist sexual health services (SHSs) and 14.0% in January-March 2017 for specialist SHSs.

Background

The English National Chlamydia Screening Programme (NCSP) recommends that sexually active 15 to 24 year-olds are-tested for chlamydia annually and on change of sexual partner. Young adults who test positive for chlamydia are at increased risk of subsequently testing positive compared to those who initially test negative [1-8]. Possible reasons for such repeat infections include non-compliance with treatment, incomplete or unsuccessful partner notification, unsafe sexual behaviours and treatment failure of the index patient or a partner [9]. In 2012-13 the NCSP carried out a consultation on whether individuals diagnosed with chlamydia should be routinely offered re-testing following a chlamydia diagnosis. The consultation found that both health professionals and young adults supported a recommendation for routine re-testing. Both groups emphasised that the offer of a re-test should be part of case management and should not replace the need for partner notification or advice on safer sex including condom use [10].
Following the consultation, the NCSP updated their recommendations for case management in August 2013, to include a routine offer of a re-test around three months after treatment completion [11]. This report accompanies the data tables on chlamydia re-testing rates by PHE Centre area (PHE-C) and upper tier local authority (UTLA) (available here by PHE-C and by UTLA for users of the HIV-STI web portal). These data tables are available on an annual basis to aid local monitoring and decision making. A re-testing audit tool is also available here. For information on the methodology and data limitations of these analyses please refer to appendix 1 and 2.

**National rates of re-testing**

Since 2013, quarterly re-testing rates for England ranged between 10.9% and 14.2% for non-specialist sexual health services (SHSs)* and between 11.5% and 14.0% in specialist SHSs. Re-testing rates in specialist SHSs have increased from 11.7% in Q1 2013 to 13.1% in Q2 2017. Positivity at re-test was consistently higher in specialist SHSs (15.8% - 18.7%) than in non-specialist SHSs (11.2% – 14.3%) (Figure 1).

---

* Sexual health services (SHSs) include both GUM (level 3) and non-GUM (level 1 & 2) SHSs. GUM or specialist SHSs refers to genitourinary medicine (GUM) and integrated GUM/sexual and reproductive health (SRH). Non-GUM or non-specialist SHSs refers to SRH services, young people’s services, online sexual health services, termination of pregnancy services, pharmacies, outreach and general practice, and other community-based settings. (For definitions of service levels (Appendix 2), see BASHH guidelines: http://www.medfash.org.uk/uploads/files/p18dtqil8116261rv19i61rh9n2k4.pdf)
Figure 1: Chlamydia re-testing rates within 7-14 weeks following a positive diagnosis and positivity at re-test by quarter, non-specialist and specialist SHSs, January 2013 – June 2017, 15-24 year-olds, England*

* Non-specialist SHS rates exclude data from UTLAs where >20% of records were missing required data items.
Local rates of re-testing

Rates of re-testing varied considerably by UTLA. Re-testing rates ranged from 0-28% (median 12% IQR: 7.9%-17.2%) in non-specialist SHSs and from 0-33% in specialist SHSs (median 13% IQR: 8.9%-15.9%) (Figure 2). Positivity at re-test is not presented by UTLA as the numbers are too low in many for meaningful interpretation.

Figure 2: Chlamydia re-testing rates within 7-14 weeks following a positive diagnosis by UT local authority, April – June 2017, 15-24 year-olds, England*

* UTLAs excluded where < 10 diagnoses. UTLAs also excluded from non-specialist SHS analyses where >20% of records were missing required data items. Of the 152 UTLAs in England, 128 for non-specialist SHSs and 149 for specialist SHSs met the criteria for inclusion in the analysis above.
## Discussion

This report provides an update for monitoring rates of chlamydia re-testing using the two national STI surveillance systems. Despite the limitations of these data (appendix 2), our findings suggest that in 2017, as few as 1 in 8 chlamydia diagnoses among young adults were followed by a re-test within 7 to 14 weeks.

Since the NCSP recommendation for offer of re-test was incorporated into case management guidance in August 2013 the surveillance data does not provide strong evidence of a change in re-testing rates at the national level in either non-specialist or specialist SHSs. However, we can only measure re-testing coverage; offer of re-test is not captured in surveillance datasets. Re-testing rates by UTLA show large variation which may be attributable to small numbers of index diagnoses. Most UTLAs have re-testing rates below 20% in both non-specialist and specialist SHSs. PHE has produced a re-testing monitoring tool [13] to allow commissioners to explore their local re-testing figures in more detail. The national audit report on chlamydia re-testing is available here. In spring 2016 PHE launched a series of Chlamydia Care Pathway workshops with local area commissioners and providers to support local teams to improve the quality and efficiency of their chlamydia screening services. The importance of re-testing is highlighted in these workshops.

Positivity at re-test is higher than the positivity seen overall in both specialist and non-specialist SHSs: 14.3% vs. 8.1% in non-specialist SHSs and 17.4% vs 11.8% in 2017 in specialist SHSs [14]. The proportion of patients who re-tested positive in specialist SHSs was consistently higher than those re-tested in non-specialist SHSs. These findings support the inclusion of offer of re-test at around three months within the NCSP case management guidance.

There are several approaches that can be taken to incorporate re-testing into the patient care pathway and different methods that could be used to recall patients [15]. Local examples are discussed in the document “Chlamydia re-testing of positive cases: models of existing practice” [16] available here. The relative cost of implementing different methods of recall for re-testing is dependent upon existing local practices.
References


Appendix 1: Data collection and methodology

Routine surveillance data on chlamydia testing from the CTAD Chlamydia Surveillance System and GUMCAD STI Surveillance System, collected by Public Health England [12], were used for this analysis. Quarterly re-testing rates (defined as the proportion of individuals with a chlamydia diagnosis for whom another test was recorded within the subsequent 7-14 weeks) among 15 to 24 year-olds were calculated for each UTLA and PHE-C for January 2013 to June 2017. Positivity at re-test was calculated for England and PHE-C areas.

Re-testing rates in non-specialist SHSs, and in specialist SHSs, were calculated separately because it is not possible to track individuals moving between specialist and non-specialist SHSs. Non-specialist SHS data were derived from CTAD and a combination of data items was used to match individuals between different non-specialist SHSs. Specialist SHS data were derived from GUMCAD and clinic-specific identification numbers were used to link unique patient records. Thus, for specialist SHSs, re-testing rates can be calculated only within (and not between) services.

The England and PHE-C totals for non-specialist SHSs excluded data from UTLAs where >20% of records were missing the required combination of data items. Specialist and non-specialist SHS data presented by UTLA also excluded any UTLA with fewer than 10 diagnoses per quarter. The proportion of UTLAs whose data were included in the analysis has improved from 75% in quarter 1 (Jan-Mar) 2013 to 84% in quarter 2 (Apr-Jun) 2017.
Appendix 2: Data limitations

The data presented here underestimate true re-testing rates due to the following limitations in the data available from the CTAD and GUMCAD national surveillance systems:

- Individuals cannot be matched across non-specialist and specialist SHSs in CTAD and GUMCAD.
- Individuals cannot be matched between specialist SHSs in GUMCAD because numbers linking patient records are unique only within a clinic.
- A proportion of non-specialist SHS records were reported without the data items required to monitor re-testing. Since monitoring began this figure has been reduced from 25% in Q1 2013 to 14% in Q2 2017 so we can be more confident in the accuracy of these re-testing estimates.

Accuracy and interpretation of monitoring re-testing rates using surveillance data could be improved by:

- Increased completion of data items submitted to CTAD;
- Better understanding of the proportion of patients who are likely to retest in a different service from their initial test, either by moving between specialist SHSs, or between specialist and non-specialist SHSs. We recommend LAs check patient pathways to determine the extent to which this may affect their data.
About Public Health England

Public Health England exists to protect and improve the nation’s health and wellbeing, and reduce health inequalities. We do this through world-class science, knowledge and intelligence, advocacy, partnerships and the delivery of specialist public health services. We are an executive agency of the Department of Health and Social Care, and are a distinct delivery organisation with operational autonomy. We provide government, local government, the NHS, Parliament, industry and the public with evidence-based professional, scientific and delivery expertise and support.

About Health Protection Report

Health Protection Report is a national public health bulletin for England and Wales, published by Public Health England. It is PHE’s principal channel for the dissemination of laboratory data relating to pathogens and infections/communicable diseases of public health significance and of reports on outbreaks, incidents and ongoing investigations.

Public Health England, Wellington House, 133-155 Waterloo Road, London SE1 8UG Tel: 020 7654 8000 www.gov.uk/phe
Twitter: @PHE_uk Facebook: www.facebook.com/PublicHealthEngland

Queries relating to this document should be directed to:
HIV and STI Department, mailto:hcai.amrdepartment@phe.gov.uk
National Infection Service, PHE Colindale,
61 Colindale Avenue, London NW9 5EQ.

© Crown copyright 2018
You may re-use this information (excluding logos) free of charge in any format or medium, under the terms of the Open Government Licence v3.0. To view this licence, visit OGL. Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.

Published June 2018
PHE publications gateway number: 2018139

PHE supports the UN Sustainable Development Goals